CHEN Hongda, LIAO Xianzhen, DU Lingbin, DONG Dong, WEI Donghua, GAO Yi, ZHENG Weifang, CHEN Jingjun, LU Ming, ZHANG Yuhan, LU Bin, LUO Chenyu, LI Na, ZHOU Yueyang, LUO Jiahui, CAI Jie, SHI Jufang, DAI Min. Evaluation of the Effectiveness of Colonoscopy, Fecal Immunochemical Test and Risk-adapted Screening Strategies in Population-based Colorectal Cancer Screening: A Multicenter Randomized Controlled Trial[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 114-123. DOI: 10.12290/xhyxzz.2022-0537
Citation: CHEN Hongda, LIAO Xianzhen, DU Lingbin, DONG Dong, WEI Donghua, GAO Yi, ZHENG Weifang, CHEN Jingjun, LU Ming, ZHANG Yuhan, LU Bin, LUO Chenyu, LI Na, ZHOU Yueyang, LUO Jiahui, CAI Jie, SHI Jufang, DAI Min. Evaluation of the Effectiveness of Colonoscopy, Fecal Immunochemical Test and Risk-adapted Screening Strategies in Population-based Colorectal Cancer Screening: A Multicenter Randomized Controlled Trial[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 114-123. DOI: 10.12290/xhyxzz.2022-0537

Evaluation of the Effectiveness of Colonoscopy, Fecal Immunochemical Test and Risk-adapted Screening Strategies in Population-based Colorectal Cancer Screening: A Multicenter Randomized Controlled Trial

Funds: 

National Natural Science Foundation of China 82173606

National Natural Science Foundation of China 82273726

Beijing Nova Program of Science and Technology Z191100001119065

Natural Science Foundation of Beijing Municipality 7202169

CAMS Innovation Fund for Medical Sciences 2017-I2M-1-006

CAMS Innovation Fund for Medical Sciences 2022-I2M-1-003

More Information
  • Corresponding author:

    DAI Min, E-mail: daimin2002@hotmail.com

  • Received Date: September 25, 2022
  • Accepted Date: November 21, 2022
  • Issue Publish Date: January 29, 2023
  •   Objective  To evaluate the feasibility and effectiveness of colonoscopy, fecal immunochemical test(FIT) and risk-adapted screening strategies in population-based colorectal cancer screening.
      Methods  Based on the randomized controlled trial of colorectal cancer screening(TARGET-C) which was carried out in 6 centers of 5 provinces in China from May 2018 to May 2021, the participants who met the inclusion criteria of the study were randomly assigned to one of the following screening intervention groups in a ratio of 1∶2∶2, which were colonoscopy group, FIT group and risk-adapted screening group(participants evaluated to be at high risk were recommended to undertake colonoscopy, those at low risk were recommended to undertake FIT and FIT positive people received colonoscopy). The 3 groups received different schemes of colorectal cancer screening, in which the colonoscopy group only received baseline screening, whereas the FIT group and the risk-adapted screening group received annual follow-up screening on the basis of baseline screening. The main outcome was the detection rate for advanced colorectal neoplasm(including colorectal cancer and advanced adenoma). The participation rate, detection rate for any neoplasm and resource load of colonoscopy among different screening groups were further analyzed.
      Results  A total of 19 373 participants meeting the inclusion and exclusion criteria were enrolled, including 8082 males(41.7%) and 11 291 females(58.3%), with an average age of (60.5±6.5) years. Among them, 3883 were in the colonoscopy group, 7793 in the FIT group, and 7697 in the risk-adapted screening group. After 1 or 3 rounds of screening(2 rounds of follow-up screening completed in FIT group and risk-adapted screening group), the overall participation was the highest for the FIT group(99.3%), followed by the risk-adapted screening group(89.2%) and the coloscopy group(42.3%). According to the intention-to-treat analysis, the detection rates of advanced neoplasm in the colonoscopy group was higher than that in the FIT group(2.76% vs. 2.17%, ORcolonoscopy vs FIT=1.30, 95% CI: 1.01-1.65, P=0.037); there were no statistically significant differences regarding the detection rates of advanced neoplasm between the colonoscopy group and the risk-adapted screening group(2.76% vs. 2.35%, ORcolonoscopy vs risk-adapted screening=1.19, 95% CI: 0.93-1.51, P=0.156), and between the risk-adapted screening group and the FIT group(2.35% vs. 2.17%, ORrisk-adapted screening vs FIT=1.09, 95% CI: 0.88-1.34, P=0.440). The number of colonoscopies needed to be performed to detect one advanced neoplasm was used as an indicator to evaluate the resource load of colonoscopy. The number was the highest for the coloscopy group(15.4), followed by the risk-adapted screening group(10.2) and the FIT group(7.8).
      Conclusions  The risk-adapted screening strategy is feasible and effective in population-based colorectal cancer screening, and could serve as an effective supplement to the traditional colonoscopy and FIT-based colorectal cancer screening strategies.
  • [1]
    Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249. DOI: 10.3322/caac.21660
    [2]
    Cardoso R, Guo F, Heisser T, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study[J]. Lancet Oncol, 2021, 22: 1002-1013. DOI: 10.1016/S1470-2045(21)00199-6
    [3]
    Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70: 145-164. DOI: 10.3322/caac.21601
    [4]
    Davidson KW, Barry MJ, Mangione CM, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement[J]. JAMA, 2021, 325: 1965-1977. DOI: 10.1001/jama.2021.6238
    [5]
    Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society[J]. CA Cancer J Clin, 2018, 68: 250-281. DOI: 10.3322/caac.21457
    [6]
    国家癌症中心中国结直肠癌筛查与早诊早治指南制定专家组. 中国结直肠癌筛查与早诊早治指南(2020, 北京)[J]. 中华肿瘤杂志, 2021, 43: 16-38. DOI: 10.3760/cma.j.cn112152-20210105-00010
    [7]
    Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer[J]. Lancet, 2019, 394: 1467-1480. DOI: 10.1016/S0140-6736(19)32319-0
    [8]
    Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know[J]. Gut, 2015, 64: 1327-1337. DOI: 10.1136/gutjnl-2014-308074
    [9]
    Peng L, Balavarca Y, Weigl K, et al. Head-to-Head Comparison of the Performance of 17 Risk Models for Predicting Presence of Advanced Neoplasms in Colorectal Cancer Screening[J]. Am J Gastroenterol, 2019, 114: 1520-1530. DOI: 10.14309/ajg.0000000000000370
    [10]
    Chen H, Li N, Shi J, et al. Comparative evaluation of novel screening strategies for colorectal cancer screening in China(TARGET-C): a study protocol for a multicentre randomised controlled trial[J]. BMJ Open, 2019, 9: e025935. DOI: 10.1136/bmjopen-2018-025935
    [11]
    Lu M, Zhang Y, Cai J, et al. Head-to-head comparison of a risk-adapted screening strategy using various risk prediction models in detecting colorectal neoplasm[J]. J Gastroenterol Hepatol, 2022, 37: 1244-1252. DOI: 10.1111/jgh.15825
    [12]
    Sung JJY, Wong MCS, Lam TYT, et al. A modified colorectal screening score for prediction of advanced neoplasia: A prospective study of 5744 subjects[J]. J Gastroenterol Hepatol, 2018, 33: 187-194.
    [13]
    Chen H, Li N, Ren J, et al. Participation and yield of a population-based colorectal cancer screening programme in China[J]. Gut, 2019, 68: 1450-1457. DOI: 10.1136/gutjnl-2018-317124
    [14]
    Chiu HM, Ching JY, Wu KC, et al. A Risk-Scoring System Combined With a Fecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms[J]. Gastroenterology, 2016, 150: 617-625. e3. DOI: 10.1053/j.gastro.2015.11.042
    [15]
    Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multi-target stool DNA testing for colorectal-cancer screening[J]. N Engl J Med, 2014, 370: 1287-1297. DOI: 10.1056/NEJMoa1311194
    [16]
    Bretthauer M, Kaminski MF, Løberg M, et al. Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial[J]. JAMA Intern Med, 2016, 176: 894-902. DOI: 10.1001/jamainternmed.2016.0960
    [17]
    王宝权, 柴晓银, 蓝柳豪, 等. 2018-2019年浙江省兰溪市结直肠癌筛查项目成本-效果分析[J]. 中国肿瘤, 2020, 29: 914-918. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU202012005.htm
    [18]
    陈宏达, 卢明, 刘成成, 等. 结肠镜、免疫法粪便隐血试验和新型风险评估筛查方案在人群结直肠癌筛查中的参与率比较及其影响因素分析[J]. 中华流行病学杂志, 2020, 41: 1655-1661.
    [19]
    王乐, 李辉章, 朱陈, 等. 浙江省2013-2018年城市居民结直肠癌筛查结果及成本效果分析[J]. 中华流行病学杂志, 2020, 41: 2080-2086. DOI: 10.3760/cma.j.cn112338-20200324-00424
    [20]
    Chen H, Lu M, Liu C, et al. Comparative Evaluation of Participation and Diagnostic Yield of Colonoscopy vs Fecal Immunochemical Test vs Risk-Adapted Screening in Colorectal Cancer Screening: Interim Analysis of a Multicenter Randomized Controlled Trial(TARGET-C)[J]. Am J Gastroenterol, 2020, 115: 1264-1274. DOI: 10.14309/ajg.0000000000000624
    [21]
    Chen X, Li H, Guo F, et al. Alcohol consumption, polygenic risk score, and early-and late-onset colorectal cancer risk[J]. EClinicalMedicine, 2022, 49: 101460.
    [22]
    Ping J, Yang Y, Wen W, et al. Developing and validating polygenic risk scores for colorectal cancer risk prediction in East Asians[J]. Int J Cancer, 2022, 151: 1726-1736.
    [23]
    Chen H, Liu L, Lu M, et al. Implications of Lifestyle Factors and Polygenic Risk Score for Absolute Risk Prediction of Colorectal Neoplasm and Risk-Adapted Screening[J]. Front Mol Biosci, 2021, 8: 685410.
  • Related Articles

    [1]YAN Xinchun, HUO Li. Evaluation of Von Hippel-Lindau Syndrome Through Novel Small Molecular Tracer 68Ga-NY104 PET/CT Imaging[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 911-915. DOI: 10.12290/xhyxzz.2024-0216
    [2]GUO Caixia, GUO Caixu, SHI Xiaoning, GUO Jinli. ChatGPT Empowered Nursing Practice: Prospects, Risks, and Countermeasures[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1170-1174. DOI: 10.12290/xhyxzz.2023-0326
    [3]XIE Mei-qing, XIE Xiao-qian. Benefits and Risks of Menopausal Hormone Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 151-156. DOI: 10.12290/xhyxzz.2021-0130
    [4]Ying XU, Ya-li XU, Zhe WANG, Yan LIN, Chang-jun WANG, Qiang SUN. Menopausal Hormone Therapy Increases the Risk of Breast Cancer:Interpretation on an Article Published in the Lancet Sep. 2019[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 621-625. DOI: 10.3969/j.issn.1674-9081.2020.05.020
    [5]Guang-yan XU, Li XU, Zi-jia LIU, Yu-guang HUANG. Predictive Value of Preoperative Assessment Tools for Perioperative Major Adverse Cardiac Event in Patients Undergoing Noncardiac Surgery[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 518-523. DOI: 10.3969/j.issn.1674-9081.2019.05.016
    [6]Ying XU, Yan LIN, Chang-jun WANG, Qiang SUN. Consensus and Controversy: Menopausal Hormone Therapy and the Risk of Breast Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(4): 332-335. DOI: 10.3969/j.issn.1674-9081.2018.04.008
    [7]Xin WANG, Xin-yu HONG, Jin-yu LI, Rui-jie ZHAO, Yu-qing YANG, Si-hua LIU, Xue-feng SUN, Wei-guo ZHU, Jun-ping FAN, Ju-hong SHI. Value of Padua Risk Assessment Model in Evaluating Venous Thromboembolism of Hospitalized Patients in the Department of Internal Medicine[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 234-241. DOI: 10.3969/j.issn.1674-9081.2018.03.009
    [8]Shuai TANG, Jie YI, Yu-guang HUANG. Cardiovascular Responses of Intubation with Shikani Seeing Optical Stylet and Macintosh Laryngoscope[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(3): 314-317. DOI: 10.3969/j.issn.1674-9081.2012.03.015
    [9]Jian WANG, Zhu-hua ZHANG, Jian-han LIU, Chun-xiao XU, Da-hai YANG, Hong HUO, Wu-yi LI. Assessment of Pre-esophageal Dysphagia: Report of 15 Cases[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(2): 162-165. DOI: 10.3969/j.issn.1674-9081.2012.02.007
    [10]Jing-hu SUI, Ye WANG, Xiao-wen LIU, Lei WANG, Dong YANG, Ling-xin WEI, Xiao-ming DENG. Effects of Different Manual Airway Maneuvers on Bonfils Intubation Fiberscope-guided Tracheal Intubation[J]. Medical Journal of Peking Union Medical College Hospital, 2011, 2(4): 338-342. DOI: 10.3969/j.issn.1674-9081.2011.04.011
  • Cited by

    Periodical cited type(7)

    1. 洪叶,牛雪花. 粪隐血实验与内镜检查在老年高危人群肠癌癌前病变及早癌筛查中的价值. 吉林医学. 2025(02): 394-397 .
    2. 朱云峰,陆恩宁,高田静,陈晓飞. 定量与定性便隐血检测用于结直肠癌组织性筛查的效果比较. 中国肿瘤. 2024(04): 287-293 .
    3. 赖方烨,张文竹,李欣怡,孙哲. 结直肠癌筛查的研究现状. 结直肠肛门外科. 2024(02): 245-248 .
    4. 张梅,杨惠雯,周瑶,蓝婷. 外泌体非编码RNA作为结直肠癌标志物的研究进展. 徐州医科大学学报. 2024(05): 375-379 .
    5. 耿志欣,裴兵. 循环血Septin9基因甲基化检测在结直肠癌筛查中的诊断价值. 现代医学与健康研究电子杂志. 2024(19): 107-110 .
    6. 周月阳,李娜,陆斌,骆晨雨,张愉涵,骆家辉,卢明,蔡洁,代敏,陈宏达. 粪便免疫化学检测在结直肠癌筛查中的价值. 中华肿瘤杂志. 2023(11): 911-918 .
    7. 胡启华,欧爱芝,王蓉,林迪莎,李红,叶新萍. 肠癌血液多基因甲基化检测对结直肠癌高危人群筛查价值的研究. 中国现代手术学杂志. 2023(05): 367-372 .

    Other cited types(2)

Catalog

    Article Metrics

    Article views (3218) PDF downloads (170) Cited by(9)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close